Search results for "LDL Cholesterol Lipoproteins"

showing 7 items of 7 documents

The cholesterol paradox in atrial fibrillation: results from the LIPIDOGRAM 2015 study

2020

Abstract Background High blood lipid levels are known risk factors for atherosclerotic cardiovascular events, but associations between lipid levels and atrial fibrillation (AF) are unclear. Some previous studies have suggested an inverse association between lipid levels and AF referred to as the “cholesterol paradox”. Purpose To examine the prevalence of AF by differing lipid levels in a large population-based study of almost 14,000 adults in Poland. Methods The LIPIDOGRAM 2015 study is a cross-sectional study of adults aged 18 years and older recruited in Poland in 2015/2016 by 438 family physicians. Poisson regression models with robust variance were used to estimate prevalence ratios (PR…

Cardiovascular eventmedicine.medical_specialtyCholesterolbusiness.industryCardiac arrhythmiaAtrial fibrillationLipid Measurementmedicine.diseaseDrug usagechemistry.chemical_compoundWaist–hip ratiochemistryInternal medicineCardiologymedicineLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European…

2016

AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% female…

EUROASPIRE InvestigatorsMaleCardiac & Cardiovascular SystemsTime FactorsEpidemiologyCARDIOVASCULAR-DISEASE PREVENTIONCoronary DiseaseComorbidity030204 cardiovascular system & hematologyOverweightlaw.invention0302 clinical medicineRandomized controlled triallawRisk FactorsPrevalenceSecondary PreventionARTERY-DISEASE030212 general & internal medicineEUROASPIREguidelinesProspective StudiesPractice Patterns Physicians'Societies MedicalSecondary preventionGLUCOSE REGULATIONSmokingcardiovascular preventionRANDOMIZED CONTROLLED-TRIALMiddle AgedClinical PracticeEuropeTreatment OutcomePractice Guidelines as TopicCardiologyLDL Cholesterol LipoproteinsFemaleGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentCardiologyHEART-DISEASERisk Assessmentrehabilitation03 medical and health sciencesYoung AdultCardiovascular preventionSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansRisk factorCARDIAC REHABILITATIONExerciseAgedScience & TechnologyTask forcebusiness.industryCardiovascular AgentsDietCross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEHealth Care SurveysCardiovascular System & CardiologySmoking CessationSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCEEuropean journal of preventive cardiology
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct

An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals

2020

Aims To improve attainment of LDL-cholesterol (LDL-c) targets, an expert group proposed an algorithm for lipid-lowering therapy during hospitalization for acute coronary syndrome and during follow-up. We aimed to assess adherence to this algorithm, and evaluate its impact on LDL-c levels and on attainment of therapeutic LDL-c targets in a population of post-acute coronary syndrome patients. Methods and results Prospective, observational study including patients admitted for acute coronary syndrome between February 2017 and September 2018. Patients admitted without statins or ezetimibe were considered ‘naïve’. Baseline LDL-c was admission LDL-c in naïve patients, and for those taking lipid-…

Malemedicine.medical_specialtyAcute coronary syndromeStatinmedicine.drug_classLow density lipoprotein cholesterol030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibeInternal medicinemedicineHumansProspective Studies030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryAnticholesteremic AgentsCholesterol LDLGeneral MedicineEzetimibePrognosismedicine.diseaseExpert groupHospitalizationCardiologyPatient ComplianceLDL Cholesterol LipoproteinsFemalelipids (amino acids peptides and proteins)Lipid loweringCardiology and Cardiovascular MedicinebusinessAlgorithmsBiomarkersFollow-Up Studiesmedicine.drugEuropean Heart Journal. Acute Cardiovascular Care
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (&lt;80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active &lt;30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

P1502Open-label ODYSSEY APPRISE study: interim data from the first 843 participants

2017

medicine.medical_specialtybusiness.industryInternal medicineInterimmedicineLDL Cholesterol LipoproteinsCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct